Tags : Pandemic

COVID-19 MedTech

Abbott Launches Pandemic Defense Coalition to Detect Future Threats

Shots: The coalition builds on Abbott’s excellence in virus surveillance and aid in analyzing virus samples for unknown diseases and detects mutations and variants including COVID-19 The goal of the Pandemic Defense Coalition is to identify new pathogens, analyze potential risk level, assess public health impact in real-time, and contain outbreaks when new virus threats […]Read More


ViewPoints Article: Medical Representatives Opinion Survey for Business Continuity with

K. K. Consulting Services has conducted this survey by contacting around 2200 medical representatives across the India using google forms.  Objective of  Survey The purpose of this survey is to design a platform for pharmaceutical sales professionals (PSP) to share their opinion about business continuity challenges faced by them due to the present COVID pandemic […]Read More

Biotech COVID-19

GSK Collaborates with Innovax to Evaluate a Vaccine Against COVID-19

Shots: The companies collaborated to assess recombinant protein-based COVID-19 XWG-03, being developed by Innovax with Xiamen University GSK will provide Innovax access to its adjuvant system for preclinical evaluation of the COVID-19 XWG-03. GSK’s adjuvants are additives used in vaccines to boost the body’s immune response to the relevant threat The COVID-19 XWG-03 is based […]Read More

COVID-19 Pharma

Roche Highlights its Response to COVID-19 Pandemic

Shots: On Mar 19, 2020, the company initiates the global P-III study in collaboration with BARDA to assess the efficacy of Actemra/RoActemra (tocilizumab, IV) + SOC vs PBO + SOC in hospitalized patients with severe COVID-19 pneumonia Roche facilitates the delivery and production of Actemra and is working continuously to increase the availability of COVID […]Read More


Seqirus’ Audenz Receives the US FDA’s Approval as the First

Shots: The US FDA has approved Audenz (Influenza A (H5N1) monovalent vaccine, adjuvanted) to protect patients aged ≥6mos. against influenza A The novel vaccine combines two technologies i.e, MF59 adjuvant and cell-based antigen manufacturing. The MF59 adjuvant and formulated prefilled syringes used in the Audenz vaccine, produced in the facility at Holly Springs, NC, supported […]Read More